Renalase-Binding Antibodies for High-Precision Detection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for detecting renalase in bodily fluids and tissues are limited by the lack of highly selective reagents, which hinders diagnosis and prognosis of renal disease, cardiovascular disease, and cancer.

Innovation Solution

Development of antibodies or binding portions thereof that specifically bind to renalase with high affinity, allowing for improved detection and potential therapeutic applications in diseases associated with renalase activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If conventional detection methods are used for renalase, then detection can be performed, but the selectivity and precision are insufficient

Engineering Contradiction:

Improvedetection precisionVSAvoidreagent complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent introduces antibodies as intermediary reagents that specifically bind to renalase, enabling precise detection. The antibodies act as mediators between the detection system and renalase, providing high selectivity and affinity without requiring complex detection devices or procedures

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent utilizes the binding affinity parameter of antibodies to renalase to achieve high detection precision. By selecting antibodies with specific affinity characteristics for renalase, the detection system achieves high precision without increasing device complexity

Inventive Principle:

Principle #35Parameter changes

2Reliability

If renalase levels are not adequately controlled, then disease progression continues, but therapeutic intervention is needed

Engineering Contradiction:

Improvedisease outcome reliabilityVSAvoidcatecholamine-induced hypertension

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent converts the harmful effect of elevated renalase (which increases catecholamines and causes hypertension) into a beneficial therapeutic target. By developing antibodies that bind to and neutralize renalase, the harmful catecholamine-induced effects are blocked, transforming the pathological process into a treatable condition

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent employs antibodies that prevent renalase from exerting its harmful effects before disease progression occurs. The therapeutic antibody binds to renalase in advance, blocking its ability to increase catecholamines and cause hypertension, thereby preventing harmful outcomes before they manifest

Inventive Principle:

Principle #9Preliminary anti-action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The use of specific renalase-binding antibodies enables enhanced detection and modulation of renalase levels, offering promising diagnostic and therapeutic avenues for renal disease, cardiovascular disease, and cancer.

Implementation Method 1

Development of antibodies or binding portions thereof that specifically bind to renalase with high affinity

Methodology Applied

Scientific EffectAntibody-antigen binding:

Data Source

PatentUS12227595B2Anti-renalase antibodies for the treatment and prevention of diseases and disorders

Publication Date: 2025.02.18 YALE UNIVERSITY

AI summary

The present invention relates to compositions and methods for binding and inhibiting renalase. In one embodiment, the renalase binding molecule inhibits renalase activity. Thus, in diseases and conditions where a reduction of renalase activity is beneficial, such inhibitory renalase binding molecules may act as therapeutics.